Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financi... (20689 21632 Deferred revenue ...)

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results

Date:11/6/2008

20,689 21,632

Deferred revenue 57,027 61,349

Deferred gain 7,323 8,680

Other long-term liabilities 11,159 5,911

Total liabilities 459,720 510,664

Commitments and contingencies

Stockholders' equity:

Preferred stock - -

Common stock 9 9

Capital in excess of par value 1,309,973 1,302,541

Accumulated other comprehensive income (478) 1,643

Accumulated deficit (1,200,872) (1,089,754)

Total stockholders' equity 108,632 214,439

Total liabilities and stockholders' equity $568,352 $725,103

(1) The consolidated balance sheet at December 31, 2007 has been derived

from the audited financial statements at that date but does not

include all of the information and notes required by generally

accepted accounting principles in the United States for complete

financial statements. Certain 2007 amounts have been reclassified

between line items to conform with the 2008 presentation.

NEKTAR THERAPEUTICS

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, except per share information)

(unaudited)

Nine Months Ended

September 30,

2008 2007

Cash flows used in operating activities:

Net loss $(1
'/>"/>

Post Your Comments:

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financi...(20689 21632 Deferred revenue ...),Health